Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer A Southeastern Cancer Study Group TrialKramer, Barnett S., M.D.; Birch, Robert, Ph.D.; Greco, Anthony, M.D.; Prestridge, Karen; DeSimone, Philip, M.D.; Omura, George, M.D.American Journal of Clinical Oncology: December 1988 - Volume 11 - Issue 6 - p 643–645 Original Article: PDF Only Buy Abstract Author InformationAuthors Cisplatin-containing regimens have shown activity in both small and non-small cell lung cancer. We therefore conducted a randomized Phase II trial of the new platinum congeners iproplatin and carboplatin in bronchogenic carcinoma. The overall response rate in chemotherapy-naive non-small cell patients with iproplatin was 3/48 (6%; 95% confidence interval 2–18%) and with carboplatin 6/50 (12%; 95% confidence interval 5–25%). The response rates in previously treated small cell patients were 0/16 and 1/18, respectively. Overall, neither agent has pronounced activity in bronchogenic carcinoma. From the University of Florida (B.S.K.), the University of Alabama at Birmingham (R.B., K.P., G.O.), Vanderbilt University (A.G.), and the University of Kentucky (P.DeS.). © Lippincott-Raven Publishers.